Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 2
1979 1
1983 1
1985 2
1987 1
1991 2
1994 3
1995 2
1997 1
1999 1
2000 1
2001 2
2010 1
2018 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year
Filters applied: . Clear all
Page 1
High-dose etoposide and marrow transplantation.
Herzig RH. Herzig RH. Cancer. 1991 Jan 1;67(1 Suppl):292-8. doi: 10.1002/1097-0142(19910101)67:1+<292::aid-cncr2820671314>3.0.co;2-7. Cancer. 1991. PMID: 1984830 Review.
Thus, etoposide was considered an ideal agent for further dose-escalation studies, given its wide range of clinical antitumor activity at standard doses, steep dose-response curve, mild bone marrow suppression, and few nonmyeloid side effects. The high-dose e …
Thus, etoposide was considered an ideal agent for further dose-escalation studies, given its wide range of clinical antitumor activity at st …
High-dose chemotherapy regimens for solid tumors.
van der Wall E, Beijnen JH, Rodenhuis S. van der Wall E, et al. Cancer Treat Rev. 1995 Mar;21(2):105-32. doi: 10.1016/0305-7372(95)90023-3. Cancer Treat Rev. 1995. PMID: 7758003 Review.
Current, predominantly small, phase I and phase II clinical trials to not adequately compare the efficacy of these regiments and patterns of dose-limiting extramedullary toxicity are emerging. Busulfan, carmustine (BCNU) and mitomycin C cause veno-occlusive disease (VOD) o …
Current, predominantly small, phase I and phase II clinical trials to not adequately compare the efficacy of these regiments and patterns of …
Differential recovery of polymorphonuclear neutrophils, B and T cell subpopulations in the thymus, bone marrow, spleen and blood of mice following split-dose polychemotherapy.
Talmadge JE, Jackson JD, Borgeson CD, Perry GA. Talmadge JE, et al. Cancer Immunol Immunother. 1994 Jul;39(1):59-67. doi: 10.1007/BF01517182. Cancer Immunol Immunother. 1994. PMID: 8044828
In these studies, we examined the effect of a maximum-tolerated, split-dose chemotherapy protocol of cyclophosphamide, cisplatin, and 1,3-bis(2-chloroethyl)-1-nitrosourea carmustine on neutrophil and lymphocyte, subpopulations in the peripheral blood (PBL), thymus, bone
In these studies, we examined the effect of a maximum-tolerated, split-dose chemotherapy protocol of cyclophosphamide, cisplatin, and 1,3-bi …
Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
Kantarjian HM, Talpaz M, LeMaistre CF, Spinolo J, Spitzer G, Yau J, Dicke K, Jagannath S, Deisseroth AB. Kantarjian HM, et al. Cancer. 1991 Jun 15;67(12):2959-65. doi: 10.1002/1097-0142(19910615)67:12<2959::aid-cncr2820671203>3.0.co;2-t. Cancer. 1991. PMID: 1675151
Fifteen patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) who were ineligible for allogeneic bone marrow transplantation (BMT) or alpha-interferon therapy were included in this study. ...Patients were treated with cyclophosphamid …
Fifteen patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) who were ineligible for allogeneic bone
Clinical management of advanced gastrointestinal cancer.
Moertel CG. Moertel CG. Cancer. 1975 Aug;36(2):675-82. doi: 10.1002/1097-0142(197508)36:2+<675::aid-cncr2820360810>3.0.co;2-a. Cancer. 1975. PMID: 168961
The nitrosoureas and Mitomycin C produce occasional regressions, but they do not match the meager effectiveness of 5-FU; and they, in addition, present the difficult problem of cumulative bone marrow suppression. Recent trials with combination regimens have g …
The nitrosoureas and Mitomycin C produce occasional regressions, but they do not match the meager effectiveness of 5-FU; and they, in additi …
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
Schilsky RL, Dolan ME, Bertucci D, Ewesuedo RB, Vogelzang NJ, Mani S, Wilson LR, Ratain MJ. Schilsky RL, et al. Clin Cancer Res. 2000 Aug;6(8):3025-31. Clin Cancer Res. 2000. PMID: 10955780 Clinical Trial.
There was no toxicity attributable to BG alone at any dose tested. Bone marrow suppression was the primary and dose-limiting toxicity of BG combined with carmustine and was cumulative in some patients. ...Bone marrow suppression, w …
There was no toxicity attributable to BG alone at any dose tested. Bone marrow suppression was the primary and dose-lim …
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO, Nikkhah G. Reithmeier T, et al. BMC Cancer. 2010 Feb 2;10:30. doi: 10.1186/1471-2407-10-30. BMC Cancer. 2010. PMID: 20122270 Free PMC article.
BACKGROUND: The prognosis for patients with recurrent glioblastoma is still poor with a median survival between 3 and 6 months. Reports about the application of carmustine (BCNU), one of the standard chemotherapeutic drugs in the treatment of newly diagnosed glioblastoma, …
BACKGROUND: The prognosis for patients with recurrent glioblastoma is still poor with a median survival between 3 and 6 months. Reports abou …
Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil).
Tschmelitsch J, Barendswaard E, Williams C Jr, Yao TJ, Cohen AM, Old LJ, Welt S. Tschmelitsch J, et al. Cancer Res. 1997 Jun 1;57(11):2181-6. Cancer Res. 1997. PMID: 9187118 Clinical Trial.
An earlier Phase I trial of 131I-labeled mAb A33 (131I-mAb A33) demonstrated bone marrow suppression as the dose-limiting toxicity, and although modest antitumor effects were seen, no normal colon toxicity was observed. In this study, a nude mouse model was u …
An earlier Phase I trial of 131I-labeled mAb A33 (131I-mAb A33) demonstrated bone marrow suppression as the dose-limiti …
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. Chapman PB, et al. J Clin Oncol. 1999 Sep;17(9):2745-51. doi: 10.1200/JCO.1999.17.9.2745. J Clin Oncol. 1999. PMID: 10561349 Clinical Trial.
PURPOSE: Several single-institution phase II trials have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen) can induce major tumor responses in 40% to 50% of stage IV melanoma patients. ...The response rate to dacarbazine was 10.2% comp …
PURPOSE: Several single-institution phase II trials have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine, and …
1.3 Bis-(2 chloroethyl)-1-nitrosourea and streptozotocin chemotherapy.
Lokich JJ, Chawla PL, Frei E. Lokich JJ, et al. Clin Pharmacol Ther. 1975 Mar;17(3):374-8. doi: 10.1002/cpt1975173374. Clin Pharmacol Ther. 1975. PMID: 123490 Clinical Trial.
The premise that STZ and BCNU are qualitatively different with regard to marrow suppression was the primary rationale of the study. The 2- and 3-drug regimes were associated with a higher incidence of severe leukopenia and thrombopenia (47% and 100%, respectively) a …
The premise that STZ and BCNU are qualitatively different with regard to marrow suppression was the primary rationale of the s …
22 results